Drug Type Monoclonal antibody |
Synonyms SCTC21, SCTC21C |
Target |
Action inhibitors |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glomerulonephritis, IGA | Phase 2 | China | 01 Jan 2025 | |
| CD38-Positive Hematologic Neoplasms | Phase 1 | China | 28 Feb 2024 | |
| Immunoglobulin Light-Chain Amyloidosis | IND Approval | China | 10 Nov 2025 | |
| Multiple Myeloma | IND Approval | China | 20 Oct 2025 | |
| Hematologic Neoplasms | IND Approval | China | 18 Jan 2024 |






